Navigation Links
Omeros Corporation Reports First Quarter 2011 Financial Results
Date:5/10/2011

SEATTLE, May 10, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the first quarter of 2011.

Financial ResultsTotal operating expenses for the three months ended March 31, 2011 were $7.7 million compared to $6.8 million for the same periods in 2010. The increase in operating expense was primarily due to increased clinical trial activities and additional employee costs. For the three months ended March 31, 2011, Omeros reported a net loss of $6.5 million, or $0.30 per share. During the same period in 2010, Omeros reported a net loss of $6.7 million, or $0.31 per share. At March 31, 2011, Omeros had cash, cash equivalents and short-term investments of $43.6 million.  

"The first quarter included several significant events for Omeros, most notably the announcement that our OMS103HP Phase 3 ACL program did not meet its prespecified primary endpoints," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "While this setback delays OMS103HP's commercialization opportunity, the meniscectomy indication for the drug remains viable and, based on strong Phase 2 data, Phase 3 preparations are underway. We also recently reported positive results from our OMS302 Phase 2b, full-factorial OMS302 cataract trial and are submitting a request to the FDA for an end-of-Phase-2 meeting. We are evaluating our multiple options and will soon finalize our clinical plans for the remainder of 2011."

Recent Highlights

  • Announced that Omeros obtained an exclusive license to novel antifibrinolytic agents for the control of surgical and traumatic bleeding.  Research on these agents was published in the February 11,
    '/>"/>

  • SOURCE Omeros Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
    2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
    3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
    4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
    5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
    6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
    7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
    8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
    9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
    10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
    11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2015)... Feb. 27, 2015 Pharmaceutical and biotech marketers ... products for the same indication. This can be a ... to prevent one of their brands from gaining market ... to recent research by benchmarking firm, Best Practices, LLC, ... brands rather than together as part of a franchise. ...
    (Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... published in the Proceedings of the National ... showed when ibrutinib (IMBRUVICA ® ) was combined ... of tumor growth was enhanced suggesting a greater ... cancers and solid tumors with the combination. IMBRUVICA ...
    (Date:2/27/2015)... Feb. 27, 2015 Securities lawyers at ... Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP ) in ... Concerned SLXP investors are encouraged to contact attorney Hamilton ... The investigation focuses upon the shareholder value of the ... would receive only $158.00 per share in cash. At ...
    Breaking Medicine Technology:New Report Details How to Expand a Pharmaceutical Product Portfolio without Cannibalizing an Established Brand 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9
    ... BIRMINGHAM, Ala. , Feb. 4 BioCryst Pharmaceuticals, ... the fourth quarter and year ended December 31, 2009 ... strides towards the goal of building an enduring and successful ... Chief Executive Officer of BioCryst Pharmaceuticals.  "Peramivir has delivered the ...
    ... REDWOOD CITY, Calif. , Feb. 3 Genomic Health, ... ended December 31, 2009 , which included 35 percent revenue growth ... revenue for the fourth quarter of 2009 increased to $39.6 million ... 2008.  Product revenue from the Onco type DX® breast cancer test ...
    Cached Medicine Technology:BioCryst Reports Fourth Quarter and Full Year 2009 Financial Results and Provides Corporate Update 2BioCryst Reports Fourth Quarter and Full Year 2009 Financial Results and Provides Corporate Update 3BioCryst Reports Fourth Quarter and Full Year 2009 Financial Results and Provides Corporate Update 4BioCryst Reports Fourth Quarter and Full Year 2009 Financial Results and Provides Corporate Update 5BioCryst Reports Fourth Quarter and Full Year 2009 Financial Results and Provides Corporate Update 6BioCryst Reports Fourth Quarter and Full Year 2009 Financial Results and Provides Corporate Update 7BioCryst Reports Fourth Quarter and Full Year 2009 Financial Results and Provides Corporate Update 8BioCryst Reports Fourth Quarter and Full Year 2009 Financial Results and Provides Corporate Update 9BioCryst Reports Fourth Quarter and Full Year 2009 Financial Results and Provides Corporate Update 10Genomic Health Announces Year-End 2009 Financial Results 2Genomic Health Announces Year-End 2009 Financial Results 3Genomic Health Announces Year-End 2009 Financial Results 4Genomic Health Announces Year-End 2009 Financial Results 5Genomic Health Announces Year-End 2009 Financial Results 6Genomic Health Announces Year-End 2009 Financial Results 7Genomic Health Announces Year-End 2009 Financial Results 8Genomic Health Announces Year-End 2009 Financial Results 9Genomic Health Announces Year-End 2009 Financial Results 10Genomic Health Announces Year-End 2009 Financial Results 11Genomic Health Announces Year-End 2009 Financial Results 12
    (Date:2/28/2015)... 28, 2015 For those people who ... the Mesothelioma Applied Research Foundation (Meso Foundation) ... March 3, starting at 9:30 AM. , The live ... The broadcast can be accessed through any browser on ... , The Symposium is a unique event that covers ...
    (Date:2/28/2015)... Louis, MO (PRWEB) February 28, 2015 ... leading provider of outsourced sales, marketing and supply ... their client, BIOTA Botanicals, is bringing its award ... Celebrated worldwide, BIOTA Botanicals’ products are specifically created ... herbal care experts, BIOTA is committed to marrying ...
    (Date:2/28/2015)... York, NY (PRWEB) February 28, 2015 ... discuss federal testosterone lawsuits that have been filed by ... for the second week in March, the Firm notes. ... Court’s website, parties involved in the federal litigation will ... address matters related to prescription therapy treatments designed to ...
    (Date:2/28/2015)... 28, 2015 On Thursday, February 26th, Forbes ... Easy For Scammers To Steal Your Data , which stresses ... hands on a DIY phishing kit, or any kind of ... on another important point about how everyone’s cyber security is ... implemented, “like compromising legitimate content management systems or blogs in ...
    (Date:2/28/2015)... Developers of FCPX plugins and theme templates ... Final Cut Pro X entitled FCPX Overlay Chromatic Grunge 6K ... total control over 6k lens dirt overlays inside Final Cut ... “FCPX Overlay Chromatic was professionally designed to add level of ... Overlay Chromatic Grunge 6K is a resourceful tool from Pixel ...
    Breaking Medicine News(10 mins):Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 2Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 3Health News:Bernstein Liebhard LLP Notes Approaching Conference in Federal Litigation that Includes Numerous Testosterone Lawsuits Filed by the Firm 4Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2
    ... Inc. announced today an initiation of Phase I clinical ... of Alzheimer,s disease. The results of Phase I studies ... on these and other results, Avineuro Pharmaceuticals, Inc. plans ... Q2 2009. Avineuro Pharmaceuticals, Inc. presented at the 9th ...
    ... Show U.S. Rx Abandonment Rate Up 34 Percent Since ... 2008BRIDGEWATER, N.J., April 7 /PRNewswire/ ... of information and business intelligence for students, professionals and ... pharmaceutical industry, today released its annual analysis of the ...
    ... services , ... Dallas, TX (Vocus) April 7, 2009 ... Blue Island, Illinois has selected Broadlane as the exclusive provider of ... approximate $25 million in annual spend., , , , ,MetroSouth Medical ...
    ... to compliment the Small Business Administration,s recent announcement of $730 million ... banks and make it easier for entrepreneurs and start-ups to get ... ... (PRWEB) April 7, 2009 -- Health Career Agents announces SBA Pre-Approval ...
    ... vital for charities - Charity websites help raise ... networks - Women in Need helps women from ... illness, rape & abuseHARTFORD, England, April 7 ... from Hartford, Cheshire, has recently completed a newly ...
    ... Intervet/Schering-Plough Animal Health today announces that the ... testing goes to Dr. Ivo Claassen for a ... Veterinary Institute (CVI), Lelystad (the Netherlands). The announcement ... an independent expert jury panel and Professor of ...
    Cached Medicine News:Health News:2008 Sees Significant Rise in Prescription Abandonment and Uptake of Generics 2Health News:2008 Sees Significant Rise in Prescription Abandonment and Uptake of Generics 3Health News:2008 Sees Significant Rise in Prescription Abandonment and Uptake of Generics 4Health News:MetroSouth Medical Center Selects Broadlane to Provide Comprehensive Supply Chain Services 2Health News:MetroSouth Medical Center Selects Broadlane to Provide Comprehensive Supply Chain Services 3Health News:MetroSouth Medical Center Selects Broadlane to Provide Comprehensive Supply Chain Services 4Health News:Health Career Agents Announces SBA Pre-Approval Program to Launch a Healthcare Recruiting Business 2Health News:Health Career Agents Announces SBA Pre-Approval Program to Launch a Healthcare Recruiting Business 3Health News:Local Web Design Agency Launches Leprosy Charity Website for Women in Need 2Health News:Dieter Luetticken Award 2008 Recognizes Development of New Vaccine Quality Control Assay 2Health News:Dieter Luetticken Award 2008 Recognizes Development of New Vaccine Quality Control Assay 3
    ... SBI RingFix is a modular external fixation ... large variety of clinical needs. Originally marketed ... has a successful 20 year history of ... Developed around the principles of the Ilizarov ...
    ... QuickLink™ Delivery System is ... designed to assemble brachytherapy ... Connectors into seed trains ... with variable seed to ...
    ... ImmunoCard STAT! EHEC is the first one-step 20 ... Toxin 1 and 2 produced by Enterohemorrhagic Escherichia ... McConkey broth overnight enrichment of fecal specimens and ... 100% specificity., The separate result for Toxin 1 ...
    Classic, stylish, and preppy, this collection features men's, women's and unisex styles....
    Medicine Products: